Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis?

Heart

Volumn 91, Issue 10, 2005, Pages 1257-1259

  Shavelle, David M ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; CALCIUM; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RAMIPRIL;

AORTA STENOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; DRUG TOLERABILITY; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATORY CELL; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SMOKING; TREATMENT OUTCOME; AORTA VALVE STENOSIS; CORONARY ARTERY ATHEROSCLEROSIS; FORECASTING; NOTE; PHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE STENOSIS; CORONARY ARTERIOSCLEROSIS; FORECASTING; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 25144519245     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.056614     Document Type: Editorial

References (24)

1. Chan KL. Is aortic stenosis a preventable disease? J Am Coll Cardiol 2003;42:593-9.
2. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53.
3. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol 1997;29:630-4.
4. Palta S, Pai AM, Gill KS, et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-502.
5. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
6. Mohler ER III, Adam LP, McClelland P, et al. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997;17:547-52.
7. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-30.
8. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-66.
9. Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endotheliai function. J Hum Hypertens 2004;18:599-606.
10. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
11. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8
12. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800-7.
13. Candida R, Allen TJ, Lassila M, et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004;109:1536-42.
14. Candida R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246-53.
15. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000;101:1586-93.
16. Chen XL, Tummala PE, Olbrych MT, et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9.
17. Foris G, Dezso B, Medgyesi GA, et al. Effect of angiotensin II on macrophage functions. Immunology 1983;48:529-35.
18. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
19. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors or the European Society of Cardiology. Eur Heart J 2004;25:1454-70.
20. Martinez SC, Henne O, Arceo A, et al. [Hemodynamic effects of oral captopril in patients with critical aortic stenosis]. Arch Inst Cardiol Mex 1990;66:322-30.
21. O'Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004;52:185-91.
22. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction-pilot study of enalapril in aortic stenosis (SCOPE-AS). Am Heart J 2004;147:E19.
23. Jiménez-Candil J, Bermejo J, Yotti R, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart 2005;91:1311-8.
24. Otto CM. Aortic stenosis. Clinical evaluation and optimal timing of surgery. Cardiol Clin 1998;16:353-73.